Latest News

Twenty-seven Alzheimer’s drugs in Phase III clinical trials and eight drugs in Phase II clinical trials may launch in the next five years, according to a revised Alzheimer's pipeline analysis presented today at the Alzheimer’s Association International Conference (AAIC). Read the full press release here.

Could changing up regulatory requirements for Alzheimer’s drugs help give desperate patients new options for treatment? A group of researchers and patient advocates think so. Read the full article here.

"The FDA Can Declare War on Alzheimer's," by George Vradenburg and Dr. Howard Fillit, chief science officer of the Alzheimer’s Drug Discovery Foundation. Read the full article here.

Each quarter, we will share a few key pieces from a variety of publications highlighting interesting advancements in Alzheimer’s, neuroscience and research more broadly. Read the full newsletter here.

To date, there are 57 Phase 2 and 23 Phase 3 ongoing clinical trials to test potential Alzheimer’s medications. Read the full article here

By 2029, more than 20 percent of people in the United States will be over the age of 65. That’s why the race to find effective treatments for Alzheimer’s disease feels urgent. Read the full article here.

Dr. David Morgan and George Vradenburg penned an op-ed in The Hill about the need for the healthcare system to prepare for innovative Alzheimer's treatments.

George Vradenburg appeared on NPR's The Diane Rehm Show to discuss the cost of Alzheimer's care and its impact on families. Read the full transcript.

According to a recent analysis by ResearchersAgainstAlzheimer's, 17 drugs are on pace to launch in the next five years.

Read the Press Release

"Alzheimer's research gets a boost," by Dr. David Morgan, CEO of the University of South Florida's Health Byrd Alzheimer's Institute.